The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Thomas E. Witzig
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Expert Testimony - Celgene (U)
Julie Vose
Research Funding - Allos Therapeutics; Celgene; Genentech/Roche; GlaxoSmithKline; Incyte; Millennium; Onyx; Pharmacyclics; Sanofi ; US Biotest
Pier Luigi Zinzani
No relevant relationships to disclose
Thomas Matthew Habermann
No relevant relationships to disclose
Joseph M. Tuscano
Honoraria - Celgene
Research Funding - Celgene
Rajni Sinha
No relevant relationships to disclose
Michael E. Williams
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Other Remuneration - Celgene
Johannes W. Drach
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Rod Ramchandren
No relevant relationships to disclose
Sevgi Kalayoglu Besisik
No relevant relationships to disclose
Lei Zhang
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Sherri Cicero
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Tommy Fu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Andre Goy
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene